DENVER, Colo. (247marketnews.com) – The following developments are worth watching, with Dermata Therapeutics (NASDAQ:DRMA), Verastem (NASDAQ:VSTM), NeOnc Technologies Holdings (NASDAQ:NTHI), Netcapital (NASDAQ:NCPL), Iambic Therapeutics (NASDAQ:IAM) and Estrella Immunopharma (NASDAQ:ESLA) advancing distinct strategies.
Dermata Therapeutics: Skincare Pivot Gets Fresh Clinical-Study Boost
Dermata Therapeutics (NASDAQ:DRMA) is moving further away from its historical pharmaceutical-development focus and toward a consumer skincare business under its Tome brand. Yesterday, the company announced positive topline results from a 31-participant cosmetic study evaluating its Tome Foundational Treatment, a once-weekly skin-renewal product. The announcement gives Dermata a new commercial talking point as it works to establish a consumer-facing business model.
According to the company, more than 71% of participants were assessed as having an overall improvement in skin appearance after just one treatment. Following four weekly treatments, 93% of participants agreed that the product was comparable to a professional in-office procedure, while 90% said they noticed more visible results compared with other products. No treatment-related adverse events were reported in the study. These are company-reported findings from a small, open-label cosmetic study, not results from a controlled clinical trial.
Verastem Oncology: Cancer-Drug Data and $250 Million Financing Move
Verastem (NASDAQ:VSTM) delivered a major clinical update on October 14 for VS-7375, its investigational KRAS G12D inhibitor, which targets a mutation implicated in several difficult-to-treat cancers. The company reported a 50% confirmed objective response rate in a subgroup of second-line pancreatic ductal adenocarcinoma patients, along with additional response data across pancreatic and non-small cell lung cancers. These early findings have put the program in focus as Verastem evaluates its next development steps.
The company also reported that it had reached alignment with the FDA on the design of a Phase 3 trial in first-line metastatic pancreatic cancer, with plans to open the trial by year-end. That is a consequential development because pancreatic cancer remains an area of substantial unmet medical need.
The news came alongside a planned CEO transition and the announcement of a $250 million offering of common stock and pre-funded warrants. CEO Daniel Paterson is expected to retire, with Michael Bailey slated to succeed him on January 1, 2027.
NeOnc Technologies Holdings: UAE Banking Expertise Meets Brain-Cancer Development
NeOnc (NASDAQ:NTHI) is combining investigational brain-cancer therapies with an international development strategy that places Abu Dhabi at the center of its regional ambitions. On October 14, the company announced the appointment of Ali Alabedin, Head of Islamic Banking Group at First Abu Dhabi Bank, to its Board of Directors. FAB reported AED 1.41 trillion in total assets as of June 30, 2026, highlighting the scale of the financial institution from which NeOnc is drawing its new board-level expertise.
The appointment could strengthen NeOnc’s financial governance and international business-development perspective as the company coordinates clinical research, regulatory requirements and potential partnerships.
Clinical results remain central to the story. NeOnc reported topline Phase 2a results for NEO100 in August, including six-month progression-free survival of 48.9% and median overall survival of 26.09 months in a 24-patient study. The next scheduled milestone is the November 17 FDA End-of-Phase 1 meeting for NEO212, where the company expects to discuss potential Phase 2 development. NeOnc also announced a $15 million registered direct offering in September and the redemption of its outstanding Series A convertible preferred stock.
Netcapital: Listing Compliance Improves, but Reporting Issues Remain
Netcapital (NASDAQ:NCPL) announced on October 14 that Nasdaq had determined it regained compliance with the exchange’s minimum bid-price requirement. The company said its closing bid remained at or above $1.00 for 10 consecutive business days between September 23 and October 6, resolving a deficiency first identified in February.
However, the update also highlighted a separate and more serious reporting issue. Netcapital remains out of compliance with Nasdaq’s requirement for timely financial reports because its annual report for the fiscal year ended April 30, 2026, and its quarterly report for the period ended July 31, 2026, were delinquent. The company has also disclosed that previously issued financial statements for fiscal years 2022 through 2025 and certain interim periods should no longer be relied upon while it evaluates potential corrections and restatements.
Netcapital has engaged Adeptus Partners as its independent registered public accounting firm to audit historical financial statements and review interim financial information.
Iambic Therapeutics: AI Drug Discovery Enters Public Markets
Iambic Therapeutics (NASDAQ:IAM) is bringing AI-driven drug discovery to public-market investors. On October 14, the company announced the pricing of its initial public offering at $16 per share, with 9.375 million common shares offered by the company and expected gross proceeds of $150 million before underwriting discounts, commissions and other offering expenses. Trading under NASDAQ: IAM is expected to begin October 15, with the offering scheduled to close today, subject to customary conditions.
The company’s platform uses AI to support molecular design and drug discovery, aiming to improve the speed and quality of early-stage pharmaceutical development. Its partnership portfolio includes collaborations with AbbVie, Bayer and Takeda, providing external validation of industry interest in its technology. On October 5, Iambic also announced that it had submitted an investigational new drug application for IAM217, a potentially brain-penetrant KIF18A inhibitor and its second wholly owned AI-discovered drug candidate.
Estrella Immunopharma: New Clinical Site Advances Brainstorm for B-Cell Lymphoma Treatment
Estrella Immunopharma (NASDAQ:ESLA) activated Intermountain Health LDS Hospital in Salt Lake City, Utah, as the fifth clinical site for its Phase I/II STARLIGHT-1 trial evaluating EB103, an investigational CD19-targeted ARTEMIS T-cell therapy for patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma. The addition expands the trial’s clinical network, which also includes UC Davis Comprehensive Cancer Center, Baylor Scott & White Research Institute, Oregon Health & Science University and University Hospitals Cleveland Medical Center. CEO Cheng Liu, Ph.D., said: “Each new site moves the dose-expansion phase forward and brings us closer to defining the path to a future pivotal study for EB103 in patients with R/R B-cell NHL.” The new site is expected to begin screening and enrolling patients after completing site initiation activities.
The multicenter, open-label Phase I/II study is evaluating EB103’s safety and efficacy at the recommended Phase II dose, with results intended to inform the company’s strategy for a potential pivotal trial. Estrella’s ARTEMIS technology, licensed from Eureka Therapeutics, is designed to redirect T cells against CD19-positive cancer cells, while its pipeline also includes EB104, a dual-targeted candidate directed at CD19 and CD22. Activation of another clinical site represents operational progress, but it does not establish treatment efficacy or guarantee that the program will advance to a pivotal study. Investors will be watching patient enrollment, safety findings, dose-expansion results and the regulatory path ahead. Trial details are available on ClinicalTrials.gov under NCT06343311 , with additional company information at Estrella Immunopharma .
About 24/7 Market News
In today’s fast-moving markets, visibility is everything and 24/7 Market News (24/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you’re an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact sales@247mnn.com to discuss how 24/7 can help accelerate your company’s visibility and valuation trajectory.
PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. 24/7 is compensated by NTHI to provide ongoing news coverage of expected upcoming catalysts and events as well as market outreach services. For further disclosure information, please click here. This should not be construed as financial or investment advice. Trading involves substantial risk; consult your financial advisor.
Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.
CONTACT:
24/7 Market News
Editor@247mnn.com
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company’s ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company’s ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company’s filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.